
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
How Immunotherapies are Changing the Treatment of Melanoma
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Read more about ipilimumab, nivolumab, and other immunotherapies being looked at in melanoma > >
Articles in this issue
almost 12 years ago
The Outlook for CAR-Modified T Cellsalmost 12 years ago
B-Cell Malignancies Faring Well With Immunotherapiesalmost 12 years ago
Update on Immunotherapy and Targeted Combination Therapiesalmost 12 years ago
Progress Made With PD-L1 as Predictive Biomarkeralmost 12 years ago
Oncolytic Viral Therapies About to Spreadalmost 12 years ago
The Future of Immunotherapy Treatments in Lung Canceralmost 12 years ago
Checking in on Checkpoint Inhibitors








































